Pfizer ROA 2010-2023 | PFE
Current and historical return on assets (ROA) values for Pfizer (PFE) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
| Pfizer ROA - Return on Assets Historical Data |
| Date |
TTM Net Income |
Total Assets |
Return on Assets |
| 2023-12-31 |
$2.12B |
$226.50B |
0.99% |
| 2023-09-30 |
$10.48B |
$215.02B |
5.06% |
| 2023-06-30 |
$21.47B |
$220.17B |
10.63% |
| 2023-03-31 |
$29.05B |
$195.62B |
14.83% |
| 2022-12-31 |
$31.37B |
$197.21B |
16.26% |
| 2022-09-30 |
$29.77B |
$195.35B |
15.75% |
| 2022-06-30 |
$29.31B |
$195.29B |
15.85% |
| 2022-03-31 |
$24.97B |
$183.84B |
13.98% |
| 2021-12-31 |
$21.98B |
$181.48B |
12.75% |
| 2021-09-30 |
$19.43B |
$179.19B |
11.74% |
| 2021-06-30 |
$12.76B |
$169.92B |
7.71% |
| 2021-03-31 |
$10.68B |
$158.82B |
6.38% |
| 2020-12-31 |
$9.16B |
$154.23B |
5.41% |
| 2020-09-30 |
$7.73B |
$178.98B |
4.48% |
| 2020-06-30 |
$13.94B |
$177.93B |
8.17% |
| 2020-03-31 |
$15.50B |
$166.34B |
9.38% |
| 2019-12-31 |
$16.03B |
$167.59B |
9.87% |
| 2019-09-30 |
$16.22B |
$170.45B |
10.11% |
| 2019-06-30 |
$12.65B |
$156.20B |
7.92% |
| 2019-03-31 |
$11.48B |
$155.42B |
7.09% |
| 2018-12-31 |
$11.15B |
$159.42B |
6.79% |
| 2018-09-30 |
$23.82B |
$167.84B |
14.24% |
| 2018-06-30 |
$22.55B |
$164.98B |
13.39% |
| 2018-03-31 |
$21.75B |
$164.61B |
12.85% |
| 2017-12-31 |
$21.31B |
$171.80B |
12.51% |
| 2017-09-30 |
$9.81B |
$172.15B |
5.76% |
| 2017-06-30 |
$8.32B |
$168.56B |
4.84% |
| 2017-03-31 |
$7.30B |
$168.78B |
4.23% |
| 2016-12-31 |
$7.22B |
$171.62B |
4.22% |
| 2016-09-30 |
$6.27B |
$178.43B |
3.69% |
| 2016-06-30 |
$7.04B |
$170.66B |
4.19% |
| 2016-03-31 |
$7.62B |
$162.93B |
4.61% |
| 2015-12-31 |
$6.96B |
$167.38B |
4.22% |
| 2015-09-30 |
$8.36B |
$170.87B |
5.07% |
| 2015-06-30 |
$8.90B |
$160.88B |
5.39% |
| 2015-03-31 |
$9.18B |
$160.64B |
5.46% |
| 2014-12-31 |
$9.14B |
$167.57B |
5.35% |
| 2014-09-30 |
$10.48B |
$171.36B |
6.09% |
| 2014-06-30 |
$10.40B |
$172.61B |
6.01% |
| 2014-03-31 |
$21.58B |
$171.81B |
12.35% |
| 2013-12-31 |
$22.00B |
$172.10B |
12.32% |
| 2013-09-30 |
$25.75B |
$175.52B |
14.15% |
| 2013-06-30 |
$26.37B |
$179.34B |
14.35% |
| 2013-03-31 |
$15.53B |
$187.40B |
8.41% |
| 2012-12-31 |
$14.57B |
$185.80B |
7.91% |
| 2012-09-30 |
$9.69B |
$182.60B |
5.25% |
| 2012-06-30 |
$10.22B |
$182.84B |
5.43% |
| 2012-03-31 |
$9.58B |
$185.68B |
5.00% |
| 2011-12-31 |
$10.01B |
$188.00B |
5.17% |
| 2011-09-30 |
$11.46B |
$196.13B |
5.86% |
| 2011-06-30 |
$8.59B |
$195.90B |
4.42% |
| 2011-03-31 |
$8.45B |
$194.96B |
4.38% |
| 2010-12-31 |
$8.26B |
$195.01B |
4.27% |
| 2010-09-30 |
$6.13B |
$191.42B |
3.10% |
| 2010-06-30 |
$8.15B |
$191.07B |
4.40% |
| 2010-03-31 |
$7.93B |
$195.11B |
4.61% |
| 2009-12-31 |
$8.64B |
$212.95B |
5.60% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$149.038B |
$58.496B |
|
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
|
